Bedaquiline: A new hope to treat multi-drug resistant tuberculosis

Current Topics in Medicinal Chemistry

Volumn 14, Issue 16, 2014, Pages 1866-1874

  Patel, Rahul V ^a   Riyaz, Sd ^b   Park, Se Won ^a  

^a Konkuk University   (South Korea)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Antituberculosis drug; Bedaquiniline; Clinical trials; Diarylquinolone; Docking; Mycobacterium tuberculosis

Indexed keywords

BEDAQUILINE; CYTOCHROME P450 3A4; ISONIAZID; PROTON PUMP; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRAZINAMIDE; RIFAMPICIN; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; DNA REPLICATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; EPOXIDATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MOLECULAR DYNAMICS; MOLECULAR MODEL; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SEQUENCE ALIGNMENT; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SYNTHESIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; DRUG DISCOVERY; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84911440058     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140929114822     Document Type: Article

References (28)

1. WHO, Global. tuberculosis report 2012, http://apps.who.int/iris/ bitstream/10665/75938/1/9789241564502_eng.pdf
2. Ginsberg, A.; Spigelman, M.; Tuberculosis: The Essentials, Fourth Edition, Chapter-14: New drugs for tuberculosis. Informa. Healthcare, 2009.
3. Cardona, P.J. Understanding Tuberculosis - New approaches to fighting against drug resistance, Chapter-9: Kolyva, A.; Karakousis, P.C. Old and New TB Drugs: Mechanisms of action and resistance. In: Mycobacterium tuberculosis/Book 2, Cardona, P.J. ed. InTech, 2011.
4. Casenghi, M. Development of new drugs for TB chemotherapy. In campaign for access to essential medicines. Medecins sans frontiers, (2006). http://www.msf.or.jp/info/pressreport/pdf/TBpipeline_ E.pdf, accessed 16 september 2012).
5. Drug Pipeline, http://www.newtbdrugs.org/pipeline.php
6. Marc, R.; de, Jonge.; Luc, H.M.; Koymans, Jérôme.; Guillemont, E.G.; Anil, K.; Koen, A. A Computational Model of the Inhibition of Mycobacterium tuberculosis ATPase by a New Drug Candidate R207910. Proteins: Stru. Fun. Bioinf., 2007, 67, 971-980.
7. Rastogi, V.K.; Girvin, M.E. Structural changes linked to proton translocation by subunit c of the ATP synthase. Nature, 1999, 402, 263-268.
8. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.V.; Eiglmeier, K.; Gas, S.; Barry C.E, 3rd.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-544.
9. Henikoff, S.; Henikoff, J.G. Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. USA, 1992, 89:10915-10919.
10. Perna, N.T.; Plunkett G, 3rd.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.; Mayhew, G.F.; Evans, P.S.; Gregor, J.; Kirkpatrick, H.A.; Posfai, Gm, Hackett, J.; Klink, S.; Boutin, A.; Shao, Y.; Miller, L.; Grotbeck, E.J.; Davis, N.W.; Lim, A.; Dimalanta, E.T.; Potamousis, K.D.; Apodaca, J.; Anantharaman, T.S.; Lin, J.; Yen, G.; Schwartz, D.C.; Welch, R.A.; Blattner, F.R. Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature, 2001, 409, 529-533.
11. Anti-Infective Drugs Advisory Committee Meeting Briefing Document. TMC207 (bedaquiline). Treatment of Patients with MDR-TB. NDA 204-384. 28 November, 2012. US Food and Drug Administration
12. Cohen, J. Infectious disease: Approval of novel TB drug celebrated- with restraint. Science, 2013, 339, 130.
13. Van Gestel, J.F.E.; Guillemont, J.E.G.; Venet, M.G.; Poignet, H.J.J.; Decrane, L.F.B.; Odds, F.C. Novel mycobacterial inhibitors. (Janssen PharmaceuticaNV) US 2005/0148581, 2005.
14. Porstmann, F.R.; Horns, S.; Bader, T. Process for preparing (alphaS, betR)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxyalpha- 1-naphthalenyl-beta-phenyl-3-quinolineethanol. (Janssen PharmaceuticaNV) WO 2006125769, 2006.
15. Saga, Y.; Motoki, R.; Makino, S.; Shimizu, Y.; Kanai, M.; Shibasaki, M. Catalytic Asymmetric Synthesis of R207910. J. Am. Chem. Soc., 2010, 132, 7905-7907.
16. Chandrasekhar, S.; KiranBabu, G.S.; Mohapatra, D.K. Practical Syntheses of (2S)-R207910 and (2R)-R207910. Eur. J. Org. Chem., 2011, 2011, 2057-2061.
17. Andries, K.; Verhasselt, P.; Guillemont, J.; Gohlmann, H.W.; Neefs, J.M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307, 223-227.
18. Lounis, N.; Veziris, N.; Chauffour, A.; Truffot-Pernot, C.; Andries, K.; Jarlier, V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother., 2006, 50, 3543- 3547.
19. Rivers, E.C.; Mancera, R.L. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov. Today, 2008, 13, 1090-1098.
20. Matteelli, A.; Carvalho, A.C.; Dooley, K.E.; Kritski, A. TMC207: The first compound of a new class of potent anti-tuberculosis drugs. Fut. Microbiol., 2010, 5, 849-858.
21. Singh, H.; Natt, N.K.; Garewal, N.; Pugazhenthan, T. Bedaquiline: a new weapon against MDR and XDR-TB. Int. J. Basic Clin. Pharmacol., 2013, 2, 96-102.
22. Guillemont, J.; Meyer, C.; Poncelet, A.; Bourdrez, X.; Andries, K. Diarylquinolines, synthesis pathways and quantitative structure-- activity relationship studies leading to the discovery of TMC207. Fut. Med. Chem., 2011, 3, 1345-1360.
23. De Jonge, M.R.; Koymans, L.H.; Guillemont, J.E.; Koul, A.; Andries, K. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins, 2007, 67, 971-980.
24. Tasneen, R.; Li, S.Y.; Peloquin, C.A.; Taylor, D.; Williams, K.N.; Andries, K.; Mdluli, K.E.; Nuermberger, E.L. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother., 2011, 55, 5485-5492.
25. Grosset, J.H.; Ammerman, N.C. Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207). Expert Rev. Anti Infect. Ther., 2013, 11, 649-651.
26. Diacon, A.H.; Dawson, R.; Von Groote-Bidlingmaier, F.; Symons, G.; Venter, A.; Donald, P.R.; Conradie, A.; Erondu, N.; Ginsberg, A.M.; Egizi, E.; Winter, H.; Becker, P.; Mendel, C.M. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smearpositive pulmonary tuberculosis. Antimicrob. Agents Chemother., 2013, 57, 2199-2203.
27. Food and Drug Administration (U.S). Anti-infective drugs advisory committee meeting briefing document TMC207 (bedaquiline). Treatment of patients with MDR-TB. NDA 204-384. 2012, Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisory Committee/UCM329260.pdf
28. World Health Organization, WHO interim guidance on the use of bedaquiline to treat MDR-TB, 2013, http://www.who.int/mediacentre/ news/notes/2013/bedaquiline_mdr_tb_20130613/en